New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2014
10:55 EDTIDRA, IDRASummer Street's chief scientific officer holds analyst/industry conference call
Chief Scientific Officer Classen discusses Idera's (IDRA) toll-like receptor antagonist (IMO-8400) for Psoriasis on an Analyst/Industry conference call to be held on March 14 at 11 am.
News For IDRA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 1, 2015
08:40 EDTIDRAIdera Pharmaceuticals granted ODD by FDA for IMO-8400
Idera Pharmaceuticals announced that the FDA has granted orphan drug designation for IMO-8400, an antagonist of the endosomal Toll-like receptors, or TLRs, 7, 8 and 9, for the treatment of diffuse large B-cell lymphoma, or DLBCL. Idera is currently conducting a clinical trial of IMO-8400 in patients with relapsed or refractory DLBCL harboring MYD88 L265P oncogenic mutation. Preclinical studies have shown that in B]cell lymphomas characterized by the MYD88 L265P oncogenic mutation, including DLBCL, TLR signaling is over-activated, thereby enabling tumor cell survival and proliferation. As a TLR antagonist, IMO-8400 inhibits TLR signaling. The objectives of the trial are to evaluate the compound's safety, tolerability and clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously.
March 31, 2015
14:49 EDTIDRAIdera adds DLBCL to other orphan designation for IMO-8400, says Piper Jaffray
Subscribe for More Information
11:03 EDTIDRAIdera Pharmaceuticals granted orphan status for lymphoma treatment
The FDA granted Idera Pharmaceuticals orphan status for its treatment of diffuse large B-cell lymphoma.
March 23, 2015
09:27 EDTIDRAIdera Pharmaceuticals Chief Medical Officer resigns
Idera Pharmaceuticals disclosed in a regulatory filing that Louis Brenner, M.D. resigned his positions as senior VP and Chief Medical Officer of Idera to accept a new role as the Chief Operating Officer of a privately-held biotechnology company. This change will become effective April 3.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use